Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcTIL cells
- Development stage
- Unknown
- Lead developer
- Instil Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EcTIL cells are a form of cell therapy involving the ex vivo expansion and reinfusion of tumor-infiltrating lymphocytes (TILs) that have been engineered or selected for enhanced anti-tumor activity. TIL therapies are designed to harness and amplify the patient’s own immune response against cancer by isolating lymphocytes from tumor tissue, expanding them in vitro, and then administering them back to the patient after preparative conditioning. The "Ec" prefix may indicate a specific engineering or selection process unique to this product, but detailed proprietary information is not available in public sources. TIL therapies are primarily being developed for solid tumors such as melanoma and other cancers refractory to standard treatments.
- Other names
- EcTIL细胞
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on EcTIL cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcTIL cells.